Cd. Hillyer et al., COMPARABLE SAFETY OF BLOOD COLLECTION IN HIGH-RISK AUTOLOGOUS DONORS VERSUS NON-HIGH-RISK AUTOLOGOUS AND DIRECTED DONORS IN A HOSPITAL SETTING, American journal of clinical pathology, 102(3), 1994, pp. 275-277
The safety of autologous blood donation by ''high-risk'' patients (tho
se with some preexisting medical conditions) has been questioned. The
authors reviewed 1393 consecutive blood donation records (207 highrisk
autologous [HRA], 665 non-high-risk autologous [NHRA], and 521 direct
ed donors [DD]) to determine the safety and outcome of blood donation
by HRA patients as compared with other donors at their center. The HRA
group included patients with a history of significant coronary artery
or cerebral vascular disease, recent seizures, cardiac arrhythmia, ch
ronic heart failure, valvular or congenital heart disease, symptomatic
dyspnea, insulin-dependent diabetes and/or current therapy with two o
r more antihypertensive medications. Those designated NHRA were all ot
her autologous donors; DD met all criteria for homologous donation. Do
nor characteristics including predonation hematocrit, pre- and postdon
ation mean arterial pressure and heart rates were similar in all group
s. Eight HRA donors (3.9%) had reactions, compared with 21 NHRA (3.2%)
and 23 DD (4.4%), a difference that was without statistical significa
nce. The reaction rate in all autologous donors (HRA and NHRA) was 3.4
%. No differences in symptoms reported, hemodynamics or reaction sever
ity were observed among the three groups (P > .05). A multiple logisti
c regression was performed within and among the groups with the risk f
actor categories listed above and medication classes including beta bl
ockers, cardiac glycosides, calcium-channel blockers, antihypertensive
agents, nitrates, and antiarrhythmic agents (X(2) = 14.9; P = .0006).
Only first-time donation (P = .0001) and cardiac glycoside usage (P =
.04) were positively associated with an untoward reaction. The author
s conclude that donation by HRA donors is at least as safe as that by
donors who meet homologous donation criteria in their population and s
etting.